Document ID: chunk:federal_register_of_legislation:F2025L00215:schedule:1:p6
Version: federal_register_of_legislation:F2025L00215
Segment Type: schedule
Provision Reference: sch 1 (pt 6/51)
Character Range: 16206–19241

1

[29] Schedule 1, Part 1, after entry for Estradiol with norethisterone in the form Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 [Maximum Quantity: 2; Number of Repeats: 5]
insert:
Estradiol with norethisterone  Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)  Transdermal  ESTALIS 250/50 (Canada)  DZ  MP NP             1  5     1
Estradiol with norethisterone  Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 (S19A)  Transdermal  ESTALIS 250/50 (Canada)  DZ  MP NP     P14238  2  5     1

[30] Schedule 1, Part 1, after entry for Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 [Maximum Quantity: 2; Number of Repeats: 5]
insert:
Estradiol with norethisterone  Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)  Transdermal  ESTALIS 140/50 (Canada)  DZ  MP NP             1  5     1
Estradiol with norethisterone  Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 (S19A)  Transdermal  ESTALIS 140/50 (Canada)  DZ  MP NP     P14238  2  5     1

[31] Schedule 1, Part 1, entry for Ethosuximide in the form Capsule 250 mg
omit from the column headed "Brand": Zarontin substitute: ZARONTIN
[32] Schedule 1, Part 1, entry for Evolocumab in the form Injection 140 mg in 1 mL single use pre-filled pen [Maximum Quantity: 2; Number of Repeats: 5]
(a) omit from the column headed "Authorised Prescriber": MP substitute: MP NP
(b) omit from the column headed "Circumstances": C15177 C15201 C15395 C15410 substitute: C16294 C16336 C16350 C16351
(c) omit from the column headed "Purposes": P15177 P15201 P15395 P15410 substitute: P16294 P16336 P16350 P16351
[33] Schedule 1, Part 1, after entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) [Brand: Ezalo Composite Pack 10mg+10mg; Maximum Quantity: 2; Number of Repeats: 5]
insert:
Ezetimibe and rosuvastatin  Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)  Oral  Ezetimibe - Rosuvastatin Sandoz 10 mg/10 mg  SZ  MP NP             1  5     1
Ezetimibe and rosuvastatin  Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)  Oral  Ezetimibe - Rosuvastatin Sandoz 10 mg/10 mg  SZ  MP NP     P14238  2  5     1

[34] Schedule 1, Part 1, after entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) [Brand: Ezalo Composite Pack 10mg+20mg; Maximum Quantity: 2; Number of Repeats: 5]
insert:
Ezetimibe and rosuvastatin  Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)  Oral